Another phase II study, the CUSTOM trial, attempted to determine efficacy of lapatinib, a HER2 tyrosine kinase inhibitor best known as a treatment for HER2-positive breast cancer, on patients with HER2 mutations. Here, ERBB2 is linked to breast cancer.